| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Valuation Report from Big Four Global Accounting Firm Sets Fair Value of Acquired IP at US$17.9 Million and Boosts NAV per share by about US$8.9
Acquisition Will Aid NewGen's Transition From IVF Services Provider to Technology-driven Innovator
BANGKOK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has received an independent valuation report (the "Report") from a Big Four global accounting firm of its recently acquired advanced cytometry intellectual property (the "IP"), the acquisition of which was initially announced on July 29, 2025. The Report sets the fair value of the IP at US$17.9 million. Together with the fair value of the advanced cytometry equipment and other assets obtained from this acquisition, the transaction has resulted in an immediate Bargain Purchase Gain for the Company of US$19.2 million and boosted the Net Asset Value ("NAV") of the Company by about US$8.9 per share as of the date of this announcement. This gain is expected to significantly enhance the Company's net profit in its year-end financial results.
Posted In: NIVF
